9:43 AM
 | 
Mar 03, 2017
 |  BC Extra  |  Company News

AZ, Sanofi sharing rights to infant RSV prophylaxis

The MedImmune LLC unit of AstraZeneca plc (LSE:AZN; NYSE:AZN) and the Sanofi Pasteur vaccines unit of Sanofi (Euronext:SAN; NYSE:SNY) said they will share rights to develop and commercialize infant respiratory syncytial virus (RSV) therapeutic MEDI8897. MedImmune is to receive €120 million ($126.9 million) up front from...

Read the full 229 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >